Comparison of the effects of continuous combined and sequential combined medroxyprogesterone acetate–estradiol treatment on the proliferation of MCF-7 cells^*

References

• Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease, and other considerations. Ann Rev Public Health 1998; 19: 55–72
   PubMed Web of Science ®Google Scholar
• Doren M. An assessment of hormone replacement therapy to prevent postmenopausal osteoporosis. Osteoporosis Int 1999; 9: 53–61
   PubMed Web of Science ®Google Scholar
• Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. J Am Med Assoc 1998; 280: 605–13
   PubMed Web of Science ®Google Scholar
• Magnusson C, Baron J A, Correia N, Bergström R, Adami H O, Persson I. Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int J Cancer 1999; 81: 339–44
   PubMed Web of Science ®Google Scholar
• Persson I, Weiderpass E, Bergkvist L, Bergström R, Schairer C. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Control 1999; 10: 253–60
   PubMed Web of Science ®Google Scholar
• Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. J Am Med Assoc 2000; 283: 485–91
   PubMed Web of Science ®Google Scholar
• Ross R K, Paganini-Hill A, Wan P C, Pike M C. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000; 92: 328–32
   PubMed Web of Science ®Google Scholar
• Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997; 350: 1047–59
   PubMed Web of Science ®Google Scholar
• Salmon R J, Ansquer Y, Asselain B, Languille O, Lesec G, Remvikos Y. Clinical and biological characteristics of breast cancers in postmenopausal women receiving hormone replacement therapy for menopause. Oncol Rep 1999; 6: 699–703
   PubMed Web of Science ®Google Scholar
• Rohan T H, Miller A B. Hormone replacement therapy and risk of benign proliferative epithelial disorders of the breast. Eur J Cancer Prev 1999; 8: 123–30
   PubMed Web of Science ®Google Scholar
• Gapstur S M, Morrow M, Sellers T A. Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women's Health Study. J Am Med Assoc 1999; 281: 2091–7
   PubMed Web of Science ®Google Scholar
• Schairer C, Gail M, Byrne C, et al. Estrogen replacement therapy and breast cancer survival in a large screening study. J Natl Cancer Inst 1999; 91: 264–70
   PubMed Web of Science ®Google Scholar
• Willis D B, Calle E E, Miracle-McMahill H L. Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States. Cancer Causes Control 1996; 7: 449–57
   PubMed Web of Science ®Google Scholar
• Cline J M, Soderqvist G, von Schoultz E, Skoog L, von Schoultz B. Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques. Am J Obstet Gynecol 1966; 174: 93–100
   Google Scholar
• Soule H D, Vazquez J, Long A, Albert S, Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 1973; 51: 1409–16
   PubMed Web of Science ®Google Scholar
• Kueng W, Silber E, Eppenberger U. Quantification of cells cultured on 96-well plates. Anal Biochem 1989; 182: 16–19
   PubMed Web of Science ®Google Scholar
• Schoonen W GEJ, Joosten J WH, Klooosterboer H J. Effects of two classes of progestagens, pregnane and 19-nortestosterone derivatives, on cell growth of human breast tumour cells: I. MCF-7 cell lines. J Steroid Biochem Mol Biol 1995; 55: 423–37
   PubMed Web of Science ®Google Scholar
• Catherino W H, Jordan V C. Nomegestrol acetate, a clinically useful 19-norprogesterone derivative which lacks estrogenic activity. J Steroid Biochem Mol Biol 1995; 55: 239–46
   PubMed Web of Science ®Google Scholar
• Jeng M H, Jordan V C. Growth stimulation and differential regulation of transforming growth factor-β1 (TGFβ1), TGFβ2, and TGFβ3 messenger RNA levels by norethindrone in MCF-7 human breast cancer cells. Mol Endocrinol 1991; 5: 1120–8
   PubMed Web of Science ®Google Scholar
• Jeng M H, Parker C J, Jordan V C. Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation. Cancer Res 1992; 52: 6539–46
   PubMed Web of Science ®Google Scholar
• van der Burg B, Kalkhoven E, Isbrücker L, DeLaat S W. Effects of progestins on the proliferation of estrogen-dependent human breast cancer cells under growth factor-defined conditions. J Steroid Biochem Mol Biol 1992; 42: 457–65
   PubMed Web of Science ®Google Scholar
• Catherine W H, Jeng M H, Jordan V C. Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism. Br J Cancer 1993; 67: 945–52
   PubMed Web of Science ®Google Scholar
• Cappelletti V, Miodini P, Fioravanti L, DiFronzo G. Effect of progestin treatment on estradiol- and growth factor-stimulated breast cancer cell lines. Anticancer Res 1995; 15: 2551–6
   PubMed Web of Science ®Google Scholar
• Lippert C, Seeger H, Wallwiener D, Mueck A O. Effect of medroxyprogesterone acetate and norethisterone on the estradiol-stimulated proliferation of MCF-7 cells. Med Sci Res 1999; 27: 595–6
   Google Scholar
• Doihara H, Takashima S, Saeki H, et al. Effect of medroxyprogesterone acetate on the cell kinetics in primary breast cancer. Gan To Kagaku Ryoho 1990; 17: 2057–62
   PubMedGoogle Scholar
• Sugiyama K, Shimizu M, Akiyama T, et al. Combined effect of Navelbine with medroxyprogesterone acetate against human breast carcinoma MCF-7 cells in vitro. Br J Cancer 1998; 77: 1737–43
   PubMed Web of Science ®Google Scholar
• Sutherland R L, Hall R E, Pang G Y, Musgrove E A, Clarke C L. Effect of medroxyprogesterone acetate on proliferation and cell cycle kinetics of human mammary carcinoma cells. Cancer Res 1988; 48: 5084–91
   PubMed Web of Science ®Google Scholar
• Yoshizumi N, Satoh K, Nishiya I. The effects of progestogens on a human endometrial cancer cell line Ishikawa and a human breast cancer cell line MCF-7. Nippon Naib Gak Zass 1985; 61: 220–7
   PubMedGoogle Scholar
• Groshong S D, Owen G I, Grimison B, et al. Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin-dependent kinase inhibitors, p21 and p27 (Kipl). Mol Endocrinol 1997; 11: 1593–607
   PubMed Web of Science ®Google Scholar
• Wren B G. Hypothesis: pulsatile release of sex steroids? A hypothesis to explain anomalies in hormonal therapy. Climacteric 2000; 3: 68–70
   PubMedGoogle Scholar
• Svensson L O, Johnson S H, Olsson S E. Plasma concentrations of medroxyprogesterone acetate, estradiol, and estrone following oral administration of Klimaxil®, Trisequence®/Provera®, and Divina®. A randomised, single-blind, triple cross-over bioavailability study in menopausal women. Maturitas 1994; 18: 229–38
   PubMed Web of Science ®Google Scholar
• Ewertz M. Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark. Int J Cancer 1988; 42: 832–8
   PubMed Web of Science ®Google Scholar
• DiSaia P J, Grosen E A, Odicino F, et al. Replacement therapy for breast cancer survivors. Cancer 1995; 76(Suppl 10)2075–8
   PubMed Web of Science ®Google Scholar
• Vassilopoulou-Sellin R. Hormone replacement therapy in breast cancer survivors. J Br Menopause Soc September, 1999; 99–101
   Google Scholar
• Wile A G, Opfell R W, Margileth D A. Hormone replacement therapy in previously treated breast cancer patients. Am J Surg 1993; 165: 372–5
   PubMed Web of Science ®Google Scholar
• Stoll B A, Parbhoo S. Treatment of menopausal symptoms in breast cancer patients. Lancet 1988; 1: 1278–9
   PubMed Web of Science ®Google Scholar
• Powles T J, Hickish T, Casey S, O'Brien M. Hormone replacement after breast cancer. Lancet 1993; 342: 60–1
   PubMed Web of Science ®Google Scholar
• Eden J A, Bush T, Nand S, Wren B G. A case-control study of combined continuous estrogen-progestin replacement therapy among women with a personal history of breast cancer. Menopause 1995; 2: 67–72
   Web of Science ®Google Scholar
• Hortobagyi G N, Hug V, Buzdar A U, Kau S W, Holmes F A, Fritsche H A. Sequential cyclic combined hormonal therapy for metastatic breast cancer. Cancer 1989; 64: 1002–6
   PubMed Web of Science ®Google Scholar
• Lønning P E, Helle S I, Johannessen D C, Ekse D, Adlercreutz H. Influence of plasma estrogen levels on the length of the disease-free interval in postmenopausal women with breast cancer. Breast Cancer Res Treat 1996; 39: 335–41
   PubMed Web of Science ®Google Scholar
• Toniolo P G, Levitz M, Zeleniuch-Jacquotte A, et al. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst 1995; 87: 190–7
   PubMed Web of Science ®Google Scholar
• Hirose K, Tajima K, Hamajima N, et al. A large-scale, hospital based case-control study of risk factors of breast cancer according to menopausal status. Jpn J Cancer Res 1995; 86: 146–54
   PubMedGoogle Scholar
• Speroff L. Postmenopausal estrogen-progestin therapy and breast cancer: a clinical response to epidemiological reports. Climacteric 2000; 3: 3–12
   PubMedGoogle Scholar
• Genazzani A R. HRT and breast cancer: is there any news? A clinician's perspective. Climacteric 2000; 3: 13–16
   PubMedGoogle Scholar